Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis

Abstract Background Andexanet alfa is approved (FDA “accelerated approval”; EMA “conditional approval”) as the first specific reversal agent for factor Xa (FXa) inhibitor-associated uncontrolled or life-threatening bleeding. Four-factor prothrombin complex concentrates (4F-PCC) are commonly used as...

Full description

Bibliographic Details
Main Authors: Olivia S. Costa, Stuart J. Connolly, Mukul Sharma, Jan Beyer-Westendorf, Mary J. Christoph, Belinda Lovelace, Craig I. Coleman
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Critical Care
Subjects:
Andexanet alfa
Four-factor prothrombin complex concentrate
Direct factor Xa inhibitor reversal
Intracranial hemorrhage
Online Access:https://doi.org/10.1186/s13054-022-04043-8

Internet

https://doi.org/10.1186/s13054-022-04043-8

Similar Items